

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| |
|--|
| Name of entity: AVITA Medical, Inc. ("Company") |
| ARBN: 641 288 155 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-----------------|
| Name of Director | Cary G. Vance |
| Date of last notice | 29 January 2026 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|--|
| Direct or indirect interest | Direct |
| Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | N/A |
| Date of change | 29 May 2026 (United States) / 30 May 2026 (Australia) |
| No. of securities held prior to change | 3,458 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") 32,313 shares of common stock of the Company (which may be represented by CDIs) 7,092 options expiring 7 June 2033, ex USD \$14.17 3,943 options expiring 6 June 2034, ex USD \$9.51 4,295 options expiring 22 January 2035, ex USD \$8.73 |
| Class | Common stock |

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

| | |
|--|---|
| Number acquired | 5,000 shares of common stock |
| Number disposed | N/A |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small> | USD \$3.0515 per share of common stock |
| No. of securities held after change | 3,458 RSUs 37,313 shares of common stock 7,092 options expiring 7 June 2033, ex USD \$14.17 3,943 options expiring 6 June 2034, ex USD \$9.51 4,295 options expiring 22 January 2035, ex USD \$8.73 |
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Purchase on the NASDAQ Stock Market LLC via AVH Employee Stock Purchase Plan |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | N/A |

+ See chapter 19 for defined terms.

For personal use only

| | |
|------------------------------|-----|
| Interest after change | N/A |
|------------------------------|-----|

Part 3 – ⁺Closed period

| | |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.

For personal use only